BIO is a curation and liquidity protocol for Decentralized Science (DeSci). Our mission is to accelerate biotechnology by giving global communities of patients, scientists and biotech professionals the ability to collectively fund, build and own tokenized biotech projects and intellectual property (IP).
The team behind BIO helped create Molecule, a tokenization platform for early-stage biomedicine, and VitaDAO, the largest decentralized community for longevity science. Building on these successes, BIO is designed to catalyze an onchain scientific economy through decentralized funding, incentives and liquidity.
The BIO token gives holders access to BIO's network of scientific communities and IP, enabling broad exposure to the DeSci economy.
Leveraging in-depth analyst evaluations, we have distilled key insights from expert assessments to provide a compelling outlook for BIO. Our analysts point to weakening fundamentals and unfavorable market sentiment, indicating considerable downside risk in the near term. Based on this in-depth expert analysis, we hold a highly cautious view of this stock. Our conclusion: BIO is a Strong Sell candidate.
BIO stock price ended at $0.024144 on 水曜日, after dropping 0.4%
On Jul 15, 2026 00:00, the price of BIO fell by 0.4%, dropping from $0.027234 to $0.024144 with 24h trading volume reaching $17.1M BIO.